Stereotaxis MAGiC Catheter Shows Promise: TD Cowen Reiterates Buy Rating

jueves, 3 de julio de 2025, 6:40 pm ET1 min de lectura
STXS--

Stereotaxis' MAGiC catheter has demonstrated a 94% acute efficacy rate and strong safety profile across various arrhythmias. Favorable workflow metrics and positive physician feedback support its prospects as a next-generation robotic ablation solution. The catheter's promising results reinforce a Buy rating from Josh Jennings at TD Cowen with a price target of $5.00.

Stereotaxis MAGiC Catheter Shows Promise: TD Cowen Reiterates Buy Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios